A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer
- 1 November 2012
- journal article
- research article
- Published by Elsevier BV in Diabetes Research and Clinical Practice
- Vol. 98 (2), 271-284
- https://doi.org/10.1016/j.diabres.2012.09.008
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance databaseActa Diabetologica, 2011
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based TherapiesGastroenterology, 2011
- A cohort study of acute pancreatitis in relation to exenatide useDiabetes, Obesity and Metabolism, 2011
- Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or SitagliptinDiabetes Care, 2010
- Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic TherapyThe New England Journal of Medicine, 2010
- Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and BenefitsDiabetes Care, 2010
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburideCurrent Medical Research and Opinion, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211)Diabetes Care, 2004